Alpha-tocopheroloxyacetic acid - Veana Therapeutics

Drug Profile

Alpha-tocopheroloxyacetic acid - Veana Therapeutics

Alternative Names: Oral Vimo-001; Oral Vimo-002; Oral Vimo-003; Oral Vimo-004; Oral Vimo-005; Vimo 001; Vimo 002; Vimo 003; Vimo 004; Vimo 005; Vimo-V001; α-TEA - Veana Therapeutics

Latest Information Update: 19 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Veana Therapeutics
  • Developer Providence Health & Services; Veana Therapeutics
  • Class Antineoplastics; Cancer vaccines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Carcinoma; Lymphoma; Sarcoma
  • Preclinical Solid tumours

Most Recent Events

  • 18 Jan 2018 Preclinical trials in Solid tumours in USA (PO) before January 2018 (Veana Therapeutics pipeline, January 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top